局部晚期头颈癌序贯加量与同步整合加量IMRT同步化疗的比较分析
该单中心回顾性匹配队列分析比较了局部晚期头颈癌根治性同步放化疗中序贯加量(68例)与同步整合加量(141例)的疗效与毒性差异。两组4年总生存、无病生存及局部/区域/远处复发无显著差异,但同步整合加量组急性3–4级吞咽困难和皮炎发生率显著更高。
要点
- 序贯加量与同步整合加量两组肿瘤学结局无显著差异。
- 同步整合加量组急性3–4级吞咽困难(82% vs 55%)和皮炎(78% vs 58%)更高。
- 同步整合加量组因急性毒性未完成处方剂量的比例更高(7% vs 0)。
核心结论
- 两种调强放疗加量方式在疾病相关结局上无差异。
- 同步整合加量组观察到更高的3–4级放射性皮炎和吞咽困难发生率,但未转化为晚期毒性差异。
- 需进一步研究评估急性毒性差异。
研究设计与样本
- 单机构回顾性匹配队列分析。
- 局部晚期头颈癌根治性同步放化疗患者,处方剂量69.3 Gy/33次。
- 序贯加量组68例,同步整合加量组141例。
- 轮廓勾画、计划评估和毒性评估由同一名经验丰富的医生完成。
- 毒性在治疗期间每周评估,随访每3个月评估一次。
主要发现
- 4年总生存率序贯加量组69.3%,同步整合加量组76.8%(p=0.13)。
- 4年无病生存率分别为63%和69%(p=0.27)。
- 局部、区域或远处无复发生存均无显著差异。
- 体重下降(p=0.291)、胃造瘘管放置(p=0.494)及胃造瘘管依赖时间(p=0.465)无显著差异。
- 急性3–4级吞咽困难(82% vs 55%,p<0.001)和皮炎(78% vs 58%,p=0.012)在同步整合加量组显著更高。
临床怎么用
- 两种加量技术均可用于局部晚期头颈癌的根治性同步放化疗。
- 选择同步整合加量时需关注急性吞咽困难和皮炎的更高风险。
局限性
- 单机构回顾性匹配队列分析。
- 轮廓勾画、计划评估和毒性评估由同一名医生完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Planning and delivery of IMRT for locally advanced head and neck cancer (LAHNC) can be performed using sequential boost or simultaneous integrated boost (SIB). Whether these techniques differ in treatment-related outcomes including survival and acute and late toxicities remain largely unexplored. METHODS: We performed a single institutional retrospective matched cohort analysis on patients with LAHNC treated with definitive chemoradiotherapy to 69.3 Gy in 33 fractions. Treatment was delivered via sequential boost (n = 68) or SIB (n = 141). Contours, plan evaluation, and toxicity assessment were performed by a single experienced physician. Toxicities were graded weekly during treatment and at 3-month follow up intervals. Recurrence-free survival, disease-free survival, and overall survival were estimated via Kaplan-Meier statistical method. RESULTS: At 4 years, the estimated overall survival was 69.3% in the sequential boost cohort and 76.8% in the SIB cohort (p = 0.13). Disease-free survival was 63 and 69% respectively (p = 0.27). There were no significant differences in local, regional or distant recurrence-free survival. There were no significant differences in weight loss (p = 0.291), gastrostomy tube placement (p = 0.494), or duration of gastrostomy tube dependence (p = 0.465). Rates of acute grade 3 or 4 dysphagia (82% vs 55%) and dermatitis (78% vs 58%) were significantly higher in the SIB group (p < 0.001 and p = 0.012 respectively). Moreover, a greater percentage of the SIB cohort did not receive the prescribed dose due to acute toxicity (7% versus 0, p = 0.028). CONCLUSIONS: There were no differences in disease related outcomes between the two treatment delivery approaches. A higher rate of grade 3 and 4 radiation dermatitis and dysphagia were observed in the SIB group, however this did not translate into differences in late toxicity. Additional investigation is necessary to further evaluate the acute toxicity differences.
引用
- Vlacich G, Stavas MJ, Pendyala P, et al. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer. Radiat Oncol. 2017. PMID: 28086954. doi:10.1186/s13014-016-0756-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。